Treatment of induced murine SLE with a peptide based on the CDR3 of an anti-DNA antibody reverses the pattern of pathogenic cytokines

Autoimmunity

Volumn 35, Issue 3, 2002, Pages 211-219

  Brosh, Naama ^a   Zinger, Heidy ^a   Mozes, Edna ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

CDR based peptide; Down regulation of SLE; Experimental lupus; Immunomodulation of cytokines

Indexed keywords

16/6 IDIOTYPIC MONOCLONAL ANTIBODY; COMPLEMENTARITY DETERMINING REGION 3 PEPTIDE; COMPLEMENTARY DNA; CYTOKINE; DNA ANTIBODY; GAMMA INTERFERON; IDIOTYPIC ANTIBODY; INTERLEUKIN 2; SYNTHETIC PEPTIDE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTINUCLEAR ANTIBODY; DNA; EPITOPE; IMMUNOGLOBULIN IDIOTYPE; MONOCLONAL ANTIBODY;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CELL CULTURE; CELL PROLIFERATION; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; DRUG EFFECT; DRUG INHIBITION; EPITOPE MAPPING; FEMALE; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; RECEPTOR UPREGULATION; SUPERNATANT; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; ANIMAL; BIOSYNTHESIS; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION;

ANIMAL; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; COMPLEMENTARITY DETERMINING REGIONS; CYTOKINES; DNA; EPITOPES, T-LYMPHOCYTE; HUMAN; IMMUNOGLOBULIN IDIOTYPES; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; MICE; SUPPORT, NON-U.S. GOV'T; ANIMALS; HUMANS;

EID: 0035986701     PISSN: 08916934     EISSN: None     Source Type: Journal    
DOI: 10.1080/08916930290024584     Document Type: Article

References (42)

1. Pathogenic idiotypes of autoantibodies in autoimmunity
2. Systemic lupus erythematosus
3. Induction of a systemic lupus erythematosus like disease in mice by a common human anti-DNA idiotype
4. The role of the 16/6 idiotype network in the induction and manifestation of systemic lupus erythematosus
5. Variable regions of autoantibodies isolated from mice with experimental systemic lupus erythematosus
6. Modulation of murine systemic lupus erythematosus with peptides based on complementarity determining regions of a pathogenic anti-DNA monoclonal antibody
7. A peptide based on the sequence of the CDR3 of a murine anti-DNA mAb is a better modulator of experimental SLE than its single amino acid substituted analogs
8. Characterization and role in experimental SLE of T cell lines specific to peptides based on CDR1 and CDR3 of a pathogenic anti-DNA monoclonal antibody
9. A peptide based on the CDR3 of an anti-DNA antibody of experimental SLE origin is a dominant T cell epitope also in (NZBXNZW)F1 lupus-prone mice
10. The role of cytokines in the immunopathogenesis of lupus
11. The cytokine network in the pathogenesis of systemic lupus erythematosus and possible therapeutic implications
12. Tumor necrosis factor and other cytokines in murine lupus
13. Kinetics of cytokine production in experimental systemic lupus erythematosus: Involvement of T helper cell 1/T helper cell 2-type cytokines in disease
14. Th1 and Th2 T helper cell subsets affect patterns of injury and outcome in glomerulonephritis
15. Solid phase synthesis
16. The pathogenic human monoclonal anti-DNA that induces experimental systemic lupus erythematosus in mice is encoded by a VH4 gene segment
17. T cell receptor alpha-chain § repertoire of pathogenic autoantibody-inducing T cells in lupus mice
18. Reversal of in vitro T cell clonal anergy by IL-2 stimulation
19. Th1 cell energy and blockade in G1a phase of the cell cycle
20. Inhibition of cell cycle progression by Rapamycin induces T cell clonal anergy even in the presence of costimulation
21. Cytokines and systemic lupus erythematosus
22. Cytokine gene profile in circulating blood mononuclear cells for patients with systemic lupus erythematosus: Increased interleukin-2 but not interleukin-4 mRNA
23. Th1 (IL-2, IFN-gamma) and Th2 (IL-10, IL-4) cytokine production by peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE)
24. Immunomodulation of murine experimental SLE-like disease by interferon-gamma
25. IFN-gamma is essential for the development of autoimmune glomerulonephritis in MRL/Ipr mice
26. Roles of interferon-gamma and interleukin-4 in murine lupus
27. In vivo treatment of (NZB X NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon
28. Experimental therapy of systemic lupus erythematosus: The treatment of NZB/W mice with mouse soluble interferon-gamma receptor inhibits the onset of glomerulonephritis
29. Serum IL-6, TNFalpha, p55 srTNFalpha, p75sr TNFalpha, srIL-2alpha levels and disease activity in systemic lupus erythematosus
30. Methotrexate treatment in murine experimental systemic lupus erythematosus (SLE); Clinical benefits associated with cytokine manipulation
31. The beneficial effects of treatment with tamoxifen and anti-oestradiol antibody on experimental systemic lupus erythematosus are associated with cytokine modulations
32. Suppression of experimental systemic lupus erythematosus (SLE) in mice via TNF inhibition by an anti-TNFα monoclonal antibody and by pentoxiphyline
33. Autoimmune manifestations in the transforming growth factor-beta 1 knockout mouse
34. Decreased production of TGF-β by lymphocytes from patients with systemic lupus erythematosus
35. Transforming growth factor-beta is the predominant paracrine inhibitor of macrophage cytokine synthesis produced by glomerular mesengial cells
36. Prevention of systemic lupus erythematosus-like disease in (NZBxNZW)F1 mice by treating with CDR1- and CDR3-based peptides of a pathogenic autoantibody
37. Molecular proper of anti-DNA induced in preautoimmune NZB/W mice by immunization with bacterial DNA
38. Both IgM and IgG anti-DNA antibodies are the products of clonally selective B cell stimulation in (NZBxNZW)F1 mice
39. A peptide derived from a polyreactive monoclonal anti-DNA natural antibody can modulate lupus development in (NZBXNZW)F1 mice
40. Antigen-specific therapy of murine lupus nephritis using nucleosomal peptides: Tolerance spreading impairs pathogenic function of autoimmune T and B cells
41. Peptide inhibition of glomerular deposition of an anti-DNA antibody
42. Immune tolerance to autoantibody-derived peptides delays development of autoimmunity in murine lupus